SCHEMBL11900977

SCHEMBL11900977

C[C@H](N)c1nc2cccnc2n1-c1ccccn1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 4/20 0.39
AKT2 P31751 2/20 0.39
ALDH1A1 P00352 1/20 0.38
IRAK4 Q9NWZ3 1/20 0.37
PDE4B Q07343 1/20 0.36
AKT3 Q9Y243 1/20 0.36
POLB P06746 2/20 0.36
PIK3CD O00329 2/20 0.35
PIK3R1 P27986 1/20 0.35
PIK3CA P42336 1/20 0.35
PIK3CB P42338 1/20 0.35
PIK3CG P48736 1/20 0.35
PDE10A Q9Y233 2/20 0.35
RAB9A P51151 1/20 0.35
MEN1 O00255 1/20 0.34
PABPC1 P11940 1/20 0.34
KMT2A Q03164 1/20 0.34
S1PR1 P21453 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12472910 1.00 AKT1 (0.39) AKT1AKT2ALDH1A1IRAK4PDE4B
SCHEMBL11901109 0.84 PDE4B (0.47) AKT1AKT2PDE4BAKT3POLB
SCHEMBL11900976 0.84 PDE4B (0.47) AKT1AKT2PDE4BAKT3POLB
SCHEMBL27168448 0.83 PDE10A (0.43) AKT1AKT2PDE4BPDE10AS1PR1
SCHEMBL30777159 0.83 PDE10A (0.43) AKT1AKT2PDE4BPDE10AS1PR1
SCHEMBL11902001 0.81 TSHR (0.42) AKT1AKT2ALDH1A1PDE4BPIK3CD
SCHEMBL13506460 0.80 PDE2A (0.43) AKT1AKT2PDE4BPIK3CDPIK3R1
Hydrochloric Acid SCHEMBL27168456 0.79 KDM4E (0.45) AKT1AKT2ALDH1A1IRAK4PDE4B
Hydrochloric Acid SCHEMBL30059607 0.79 KDM4E (0.45) AKT1AKT2ALDH1A1IRAK4PDE4B
Hydrochloric Acid SCHEMBL27168455 0.79 KDM4E (0.45) AKT1AKT2ALDH1A1IRAK4PDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8653089-B2 Heterocyclic compounds and methods of use F. HOFFMANN-LA ROCHE AG (CH) 2014-02-18 US disclosed
US-8653089-B2 Heterocyclic compounds and methods of use F. HOFFMANN-LA ROCHE AG (CH) 2014-02-18 US disclosed
US-8653089-B2 Heterocyclic compounds and methods of use F. HOFFMANN-LA ROCHE AG (CH) 2014-02-18 US disclosed
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-08-09 US disclosed
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-08-09 US disclosed
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE PIK3CA, PIK3CD, AKT3 AKT1 5/4885AKT2 4/4885ALDH1A1 1680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.